BLTE BELITE BIO INC

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, is available through its website (https://). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on , , ,  or visit us at .

Media and Investor Relations Contact:

Jennifer Wu



Julie Fallon



EN
12/03/2024

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare Hou...

Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference being held virtually on May 21 and 22, 2024. The Company will host a fireside chat at 3:00 pm ET ...

May 14, 2024 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports First-Quarter 2024 Financial Results and Provides C...

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ≤18 years) (p

May 14, 2024 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect...

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference being held in New York, NY, on May 20, 2024. The Company will host a fireside chat at 3:30 pm ET. A webcast of...

May 13, 2024 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2...

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024. Webcast InformationDate: Tuesday, May 14...

May 8, 2024 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unm...

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative re...

May 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch